protocolSection identificationModule nctId: NCT06319872, orgStudyIdInfo id: STUDY00009118, briefTitle: The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-04-15, completionDateStruct date: 2025-04-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Rochester, class: OTHER, descriptionModule briefSummary: Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder., conditionsModule conditions: Alcohol Use Disorder, conditions: Retinal Dystrophies, conditions: Age-Related Macular Degeneration, conditions: Retinitis Pigmentosa, conditions: Stargardt Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Oral disulfiram, outcomesModule primaryOutcomes measure: mean change in Best Corrected Visual Acuity (BCVA) score assessed by ETDRS, secondaryOutcomes measure: mean change in total contrast sensitivity score using Pelli-Robson charts, secondaryOutcomes measure: mean change in light-adapted microperimetry sensitivity assessed using standard MAIA microperimetry equipment, secondaryOutcomes measure: mean change in outer retinal thickness assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), secondaryOutcomes measure: mean change in fundus autofluorescence (FAF), secondaryOutcomes measure: number of participants with retinal anatomy changes assessed using fundus photos, secondaryOutcomes measure: mean change in visual field perimetry using full-field stimulus test, secondaryOutcomes measure: mean change in isopter constriction using Goldmann visual field, secondaryOutcomes measure: mean change in size of scotomas using Goldmann visual field, secondaryOutcomes measure: mean change in cone and rod latency assessed using Full field electroretinogram (ffERG), secondaryOutcomes measure: mean change in cone and rod amplitude assessed using Full field electroretinogram (ffERG), secondaryOutcomes measure: mean change in cone and rod latency assessed using multifocal electroretinogram (mfERG), secondaryOutcomes measure: mean change in cone and rod amplitude assessed using multifocal electroretinogram (mfERG), secondaryOutcomes measure: mean change in National Eye Institute-Visual Functioning Questionnaire 25 composite score., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Flaum Eye Institute, University of Rochester Medical Center, city: Rochester, state: New York, zip: 14642, country: United States, contacts name: Gary Gagarinas, role: CONTACT, email: gary_gagarinas@urmc.rochestere.edu, contacts name: Alex Levin, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.15478, lon: -77.61556, hasResults: False